# 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

> **NCT05204927** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Curium US LLC** · enrollment: 439 (actual)

## Conditions studied

- Metastasis From Malignant Tumor of Prostate

## Interventions

- **DRUG:** 177Lu-PSMA-I&T
- **DRUG:** Abiraterone with Prednisone or Enzalutamide

## Key facts

- **NCT ID:** NCT05204927
- **Lead sponsor:** Curium US LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-14
- **Primary completion:** 2024-08-02
- **Final completion:** 2029-02
- **Target enrollment:** 439 (ACTUAL)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05204927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05204927, "177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05204927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*